Physician
Desert Hematology-Oncology Medical Group INC
Desert Hematology-Oncology Medical Group INC was paid $5.01M by Medicaid between Jan 2018 and Nov 2024, across 39 billing codes. Its largest line is J1439, Injection, ferric carboxymaltose, 1 mg — 37% of everything it billed.
33Billing provider infoDESERT HEMATOLOGY-ONCOLOGY MEDICAL GROUP INC
RANCHO MIRAGE, CA 92270
RANCHO MIRAGE, CA 92270
33aNPI1427069368assigned 08/09/2006
33bProvider typeHematology & Oncology Physician
28Total paid$5.01M
24GClaims63,774
24DCodes billed39
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Hematology & Oncology Physician providers in California
Rank by total paid#5 of 180
Median peer was paid$26K
This provider vs. median195×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,730 | $160K | |
| 2019 | 5,738 | $190K | |
| 2020 | 5,331 | $335K | |
| 2021 | 9,281 | $536K | |
| 2022 | 10,210 | $1.08M | |
| 2023 | 13,091 | $1.41M | |
| 2024incomplete | 13,393 | $1.30M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J1439 | Injection, ferric carboxymaltose, 1 mg | 37% | 2,439 | 1,668 | $1.84M |
| J9271 | Injection, pembrolizumab, 1 mg | 12% | 55 | 49 | $614K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 9.3% | 13,697 | 12,502 | $464K |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 6.6% | 195 | 145 | $332K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 5.8% | 681 | 460 | $290K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.4% | 3,978 | 2,867 | $220K |
| J0897 | Injection, denosumab, 1 mg | 4.1% | 133 | 131 | $204K |
| Q5130 | Injection, pegfilgrastim-pbbk (fylnetra), biosimilar, 0.5 mg | 3.2% | 117 | 79 | $158K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 3.0% | 5,902 | 3,797 | $150K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.9% | 4,924 | 3,062 | $147K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 2.1% | 2,295 | 2,048 | $105K |
| 96367 | 1.8% | 2,439 | 1,523 | $92K |
27 more codes
| 99213 | Doctor's office visit, returning patient (routine) | 1.7% | 3,800 | $84K |
| 99204 | Doctor's office visit, new patient (more involved) | 1.2% | 920 | $62K |
| 99205 | Prolong outpt/office vis | 1.1% | 787 | $56K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,228 | $41K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,213 | $38K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 1,388 | $26K |
| 96417 | <1% | 919 | $24K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 742 | $24K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 189 | $9K |
| 96415 | <1% | 355 | $7K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,169 | $4K |
| 96411 | <1% | 247 | $4K | |
| 96523 | <1% | 103 | $3K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,997 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,701 | $2K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,009 | $2K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 953 | $2K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 53 | $1K |
| J3490 | Unclassified drugs | <1% | 146 | $887.97 |
| 99070 | <1% | 109 | $783.18 | |
| 96401 | <1% | 45 | $576.16 | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 27 | $521.54 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 314 | $464.46 |
| 99195 | <1% | 27 | $390.84 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 56 | $264.80 |
| 80053 | Comprehensive metabolic panel | <1% | 263 | $45.86 |
| 36415 | Collection of venous blood by venipuncture | 0% | 159 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDAVIS, TYLER (AUTHORIZED OFFICIAL)